Nearly 30% of the funding poured into healthcare startups last year, including for biotechs, went to companies leveraging ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.